IBRX.NASDAQImmunitybio, INC
DEF 14A: ImmunityBio Seeks Stockholder Approval for Equity Incentive Plan Amendment at 2024 Annual Meeting
Sentiment:
Proxy Statement
ImmunityBio's upcoming annual meeting on June 11, 2024, will include proposals for director elections, an equity incentive plan amendment, executive compensation approval, and auditor ratification.
Summary
- ImmunityBio is holding its 2024 annual meeting of stockholders virtually on June 11, 2024.
- Stockholders will vote on four proposals: electing nine directors, approving an amendment to the 2015 Equity Incentive Plan to increase the number of shares by 19,900,000, approving executive compensation on an advisory basis, and ratifying the selection of Ernst & Young LLP as the independent auditor.
- The board recommends voting for all proposals.
- As of April 17, 2024, there were 677,036,411 shares of common stock outstanding.
- Dr. Patrick Soon-Shiong and his affiliates own approximately 78.7% of the company's outstanding common stock and intend to vote in favor of all proposals.
- The proposed amendment to the 2015 Equity Incentive Plan would increase the total number of shares available for issuance to 51,988,415, representing approximately 7.7% of outstanding common stock as of March 31, 2024.
- The company believes the additional shares are needed to attract and retain employees.
- If the amendment is not approved, the company may need to increase cash compensation, which could negatively impact cash flow.
- The company's executive compensation program aims to align executive interests with those of stockholders.
- The board values stockholder views on executive compensation and will consider the outcome of the advisory vote.
- The next say-on-pay vote is expected at the 2027 annual meeting.
- The company has a compensation recovery (clawback) policy in place.
- The company has related-party transactions, including debt and service agreements with entities affiliated with Dr. Soon-Shiong.
- The company has a written Related Party Transactions Policy.
- Stockholders must submit proposals for the 2025 annual meeting by December 27, 2024, and comply with SEC Rule 14a-8.
- Advance notice for director nominations must be received between February 15, 2025, and March 17, 2025.
Sentiment
Score: 6
Explanation: The document is primarily informational, outlining the proposals for the annual meeting. The sentiment is neutral, with a slight positive leaning due to the company's efforts to attract and retain talent.
Positives
- The company is taking steps to ensure it can attract and retain high-quality employees by proposing an increase in the share reserve for the equity incentive plan.
- The company has a compensation recovery (clawback) policy in place, which is a positive governance practice.
- The company is providing stockholders with the opportunity to vote on executive compensation and auditor ratification.
Negatives
- If the proposed amendment to the 2015 Equity Incentive Plan is not approved, the company may need to increase cash compensation, which could negatively impact cash flow.
- The company has significant related-party debt and transactions, which could raise concerns about potential conflicts of interest.
Risks
- Failure to obtain stockholder approval for the equity incentive plan amendment could hinder the company's ability to attract and retain talent.
- Increased cash compensation in lieu of equity awards could negatively impact the company's cash flow.
- Related-party transactions could raise concerns about potential conflicts of interest and the fairness of these transactions to minority stockholders.
- The company's dependence on Dr. Soon-Shiong and affiliated entities for financing could pose a risk if these sources of funding become unavailable.
Future Outlook
The company is seeking to increase the number of shares authorized for issuance under the 2015 Equity Incentive Plan to attract and retain employees.
Management Comments
- Richard Adcock, Chief Executive Officer and President, expressed gratitude for stockholders' ongoing support and continued interest in ImmunityBio, Inc.
Industry Context
The document does not provide specific details on how this announcement relates to broader industry trends or competitors, but the need to attract and retain talent is a common challenge in the biotechnology industry.
Comparison to Industry Standards
- The document does not provide specific details on how the company's results compare to global benchmarks.
- The document does not provide specific details on how the company's projects compare to global benchmarks.
- The document does not provide specific details on how the company's results compare to comparible companies.
Related Party Transactions
- The company has related-party transactions, including debt and service agreements with entities affiliated with Dr. Soon-Shiong.
- On December 23, 2014, the company entered into a subscription and investment agreement (Cambridge Subscription Agreement), a registration rights agreement (Cambridge Registration Rights Agreement), and a reclassification agreement (Reclassification Agreement) with Cambridge relating to the private placement of our Class A common stock.
- On June 18, 2015, we entered into the Cambridge Nominating Agreement, pursuant to which Cambridge has the right to designate one individual to be nominated and recommended for election by the Board for as long as Cambridge and/or its affiliates directly own more than 20% of the issued and outstanding shares of our common stock, subject to adjustment for stock splits, stock dividends, recapitalizations and similar transactions.
Stakeholder Impact
- Approval of the equity incentive plan amendment could benefit employees by providing them with equity-based compensation.
- Stockholders could benefit from the company's ability to attract and retain talent, which could lead to improved performance.
- The outcome of the say-on-pay vote will reflect stockholders' views on executive compensation.
Next Steps
- Stockholders will vote on the proposals at the annual meeting on June 11, 2024.
- The company will implement the approved proposals, including the equity incentive plan amendment and the ratification of the auditor.
Key Dates
| Date | Description |
|---|---|
| 2014-12-23 | Date of original subscription and investment agreement with Cambridge Equities, LP. |
| 2015-03 | Dr. Simon appointed president, chief executive officer and chairman of Brink Biologics Inc. |
| 2015-07 | ImmunityBio IPO completed. |
| 2015-07-27 | Date the company's shares of common stock were registered pursuant to a registration statement on Form S-1. |
| 2015-08 | Effective date of amended and restated shared services agreement with NantWorks. |
| 2015 | Date of facility license agreement with NantWorks for office space in Culver City, California. |
| 2016-06 | Date of amended and restated shared services agreement with NantWorks. |
| 2016-07 | Start date of lease agreement with 605 Doug St, LLC. |
| 2017-02 | Start date of lease agreement with Duley Road, LLC. |
| 2018-08 | Date of supply agreement with NCSC. |
| 2019-07 | Start date of second floor lease agreement with Duley Road. |
| 2019-09 | Start date of first floor lease agreement with Duley Road. |
| 2020-10 | Richard Adcock appointed Chief Executive Officer. |
| 2020-10 | Special Committee established in connection with the merger between NantKwest, Inc. and NantCell, Inc. |
| 2020-10-20 | Date of Offer of Employment letter with Richard Adcock. |
| 2020-08-03 | Date of Offer of Employment letter with David Sachs. |
| 2021-01-01 | Effective date of lease agreement with 605 Nash, LLC. |
| 2021-03-09 | Merger between NantKwest, Inc. and NantCell, Inc. closed. |
| 2021-03 | David Sachs appointed Chief Financial Officer. |
| 2021-03 | Barry J. Simon appointed Chief Corporate Affairs Officer. |
| 2021-03 | John Owen Brennan, Wesley Clark, Linda Maxwell, and Christobel Selecky appointed to the Board. |
| 2021-05 | Amendment to Initial Premises lease with 605 Nash, LLC. |
| 2021-08-11 | Dr. Soon-Shiong appointed Global Chief Scientific and Medical Officer. |
| 2021-09-27 | Date of Membership Interest Purchase Agreement with Nant Capital. |
| 2021-10-01 | Start date of lease agreement with 420 Nash, LLC. |
| 2021-12-17 | Date of $300.0 million promissory note with Nant Capital. |
| 2022-05-06 | Amendment to facility license agreement with NantWorks. |
| 2022-05-31 | Date of lease termination agreement with Nant Capital for 557 South Douglas Street. |
| 2022-08-31 | Date of amended and restated promissory note with Nant Capital. |
| 2022-08-31 | Date of $125.0 million promissory note with Nant Capital. |
| 2022-12-12 | Date of $50.0 million promissory note with Nant Capital. |
| 2023-03 | Cheryl L. Cohen appointed Lead Independent Director. |
| 2023-03-31 | Date of $30.0 million promissory note with Nant Capital. |
| 2023-06-13 | Date of $30.0 million promissory note with Nant Capital. |
| 2023-08-31 | Date of lease termination agreement with 23 Alaska, LLC. |
| 2023-09-11 | Date of stock purchase agreement with Nant Capital, NantMobile and NCSC. |
| 2023-09-11 | Date of $200.0 million convertible promissory note with Nant Capital. |
| 2023-11-29 | Effective date of the Board's adoption of a compensation recovery policy. |
| 2023-12-29 | Date of amended and restated promissory note with Nant Capital. |
| 2024-04-17 | Record date for the annual meeting. |
| 2024-05-01 | Date of proxy statement. |
| 2024-06-11 | Date of the annual meeting. |
| 2024-12-27 | Deadline for submitting stockholder proposals for the 2025 annual meeting. |
| 2025-02-15 | Earliest date for submitting advance notice for director nominations for the 2025 annual meeting. |
| 2025-03-17 | Latest date for submitting advance notice for director nominations for the 2025 annual meeting. |
| 2025-04-12 | Deadline for submitting notice under SEC Rule 14a-19 for director nominees for the 2025 annual meeting. |
Keywords
Equity Incentive Plan, Annual Meeting, Executive Compensation, Director Election, Auditor Ratification, Related Party Transactions, Stockholders, ImmunityBio
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.